Focal Epilepsy With and Without Secondary Generalization

Neurology
0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

I
IQVIANC - Durham
1 program
CenobamateN/A1 trial
Active Trials
NCT06716801Recruiting300Est. Mar 2027
UP
UCB PharmaBelgium - Brussels
1 program
LacosamideN/A1 trial
Active Trials
NCT01673282Completed315Est. Jul 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
IQVIACenobamate
UCB PharmaLacosamide

Clinical Trials (2)

Total enrollment: 615 patients across 2 trials

Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spain

Start: Dec 2024Est. completion: Mar 2027300 patients
N/ARecruiting

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy

Start: Jul 2012Est. completion: Jul 2015315 patients
N/ACompleted

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 615 patients
2 companies competing in this space